Table 4. Peptide Map Sequence Coverage.
| Hetero AB | Homo A | Homo B | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| |
detected residues |
total residuesa |
coverage |
|
detected residues |
total residuesa |
coverage |
|
detected residues |
total residuesa |
coverage |
| HC(A) |
440 |
450 |
97.8% |
|
440 |
450 |
97.8% |
|
N/A |
N/A |
N/A |
| HC(B) |
440 |
450 |
97.8% |
|
N/A |
N/A |
N/A |
|
440 |
450 |
97.8% |
| LC |
215 |
215 |
100% |
|
215 |
215 |
100% |
|
215 |
215 |
100% |
| overall | 1095 | 1115 | 98.2% | 655 | 665 | 98.5% | 655 | 665 | 98.5% | ||
a. Both heavy chain A and B are based on trastuzumab with glycine addition on the N-terminus. N-terminal glycine is not included in the residue count.